Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Bruce Sachs Biography and Net Worth

Director of Vertex Pharmaceuticals

Mr. Sachs joined our Board in 1998 and is the Board's lead independent director. Mr. Sachs is a General Partner at Charles River Ventures, a venture capital firm he joined in 1999. From 1998 to 1999, he served as Executive Vice President and General Manager of Ascend Communications, Inc. From 1997 until 1998, Mr. Sachs served as President and Chief Executive Officer of Stratus Computer, Inc. From 1995 to 1997, he served as Executive Vice President and General Manager of the Internet Telecom Business Group at Bay Networks, Inc. From 1993 to 1995, he served as President and Chief Executive Officer of Xylogics, Inc. Mr. Sachs holds a B.S.E.E. in electrical engineering from Bucknell University, an M.E.E. in electrical engineering from Cornell University, and an M.B.A. from Northeastern University.

What is Bruce I. Sachs' net worth?: The estimated net worth of Bruce I. Sachs is at least $15.89 million as of August 1st, 2024. Mr. Sachs owns 40,000 shares of Vertex Pharmaceuticals stock worth more than $15,890,800 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Sachs may own. Learn More about Bruce I. Sachs' net worth.
How do I contact Bruce I. Sachs?: The corporate mailing address for Mr. Sachs and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Bruce I. Sachs' contact information.
Has Bruce I. Sachs been buying or selling shares of Vertex Pharmaceuticals?: Bruce I. Sachs has not been actively trading shares of Vertex Pharmaceuticals within the last three months. Most recently, Bruce I. Sachs sold 5,295 shares of the business's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $508.00, for a transaction totalling $2,689,860.00. Following the completion of the sale, the director now directly owns 40,000 shares of the company's stock, valued at $20,320,000. Learn More on Bruce I. Sachs' trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 23 times. They sold a total of 79,177 shares worth more than $36,823,476.56. The most recent insider tranaction occured on November, 15th when EVP David Altshuler sold 15 shares worth more than $7,178.40. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 11/15/2024.

Bruce I. Sachs Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/1/2024	Sell	5,295	$508.00	$2,689,860.00	40,000
5/22/2024	Sell	7,073	$448.00	$3,168,704.00	40,000
11/6/2023	Sell	11,250	$385.00	$4,331,250.00	40,000
7/17/2023	Sell	11,250	$356.75	$4,013,437.50	40,000
4/12/2023	Sell	21,300	$326.73	$6,959,349.00	41,210
11/10/2020	Buy	15,000	$217.36	$3,260,400.00	18,035
5/7/2020	Sell	45,000	$269.80	$12,141,000.00	33,710
1/9/2015	Sell	9,861	$125.04	$1,233,019.44
11/28/2014	Sell	10,000	$120.03	$1,200,300.00
11/6/2014	Sell	9,900	$115.21	$1,140,579.00
11/5/2014	Sell	30,100	$112.62	$3,389,862.00
10/24/2013	Sell	8,300	$77.06	$639,598.00
7/24/2013	Sell	8,300	$85.50	$709,650.00
6/21/2013	Sell	8,300	$75.93	$630,219.00
5/14/2013	Sell	60,000	$81.15	$4,869,000.00

Bruce I. Sachs Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $397.27

$386.49

$401.31

50 Day Range

MA: $470.41

$396.64

$516.74

2 Week Range

Now: $397.27

$377.85

$519.88

Volume

6,202,268 shs

Average Volume

1,238,190 shs

Market Capitalization

$102.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.